Aura Biosciences, Inc. 4

Director David Michael Johnson received a 15,000-share RSU award and a stock option for 30,000 shares of Aura Biosciences common stock at $6.21 per share as part of equity compensation, increasing his direct holdings to 194,167 shares.

On June 11, 2026, Aura Biosciences, Inc. director David Michael Johnson received two equity-based compensation grants: 15,000 shares of common stock in the form of restricted stock units that will vest in full on the earlier of June 11, 2027 or the next annual stockholder meeting, and a stock option for 30,000 shares at an exercise price of $6.21 per share, also vesting in full on the earlier of June 11, 2027 or the next annual meeting, both under the company’s 2021 Stock Option and Incentive Plan. Following these awards, Johnson’s direct ownership increased to 194,167 common shares, and he also continues to have indirect beneficial interests in 75,000 shares held by the NEJ09 Irrevocable Trust, 75,000 shares held by the NEJ12 Irrevocable Trust, and 139,672 shares held by Velocity Capital Management LLC, for which he is trustee or sole member, respectively. No open-market purchases or sales were reported; the filing reflects routine director compensation in equity form.

Filing Facts

CIK

1501796

Ticker

AURA

Form

4

Source Type

fda

Accession

0001193125-26-271168

Alert Tier

5